Illumina Inc
NASDAQ:ILMN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
70.3
144.22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
ILMN
stock under the Base Case scenario is
133.65
USD.
Compared to the current market price of 134.95 USD,
Illumina Inc
is
Overvalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Illumina Inc.
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Intense competition from emerging long-read and single-molecule sequencing technologies could erode Illumina’s dominant market share, especially if newer platforms offer lower costs or superior accuracy that siphon demand from its core reagent and instrument sales.
Regulatory scrutiny tied to the Grail acquisition and potential antitrust setbacks may result in forced divestitures, significant legal expenses, or delays in integrating Grail’s liquid biopsy offerings into Illumina’s product portfolio, stalling strategic growth plans.
Weakness in external research funding—particularly from government grants—could reduce demand for Illumina’s high-throughput platforms, as budget-constrained labs prioritize lower-capacity instruments or postpone major capital expenditures.
Illumina’s gold-standard position in next-generation sequencing underpins strong recurring revenues from instruments and consumables, supported by a large installed base that continually drives reagent demand and service contracts.
The accelerated shift toward personalized medicine and population genomics initiatives worldwide expands Illumina’s potential customer base, boosting both instrument placements and ongoing consumables usage for large-scale projects.
Illumina’s continued innovation in high-throughput and mid-throughput systems helps the company capture both premium and cost-sensitive segments, protecting margins and maintaining brand leadership against emerging competitors.
Revenue & Expenses Breakdown
Illumina Inc
Balance Sheet Decomposition
Illumina Inc
| Current Assets | 2.8B |
| Cash & Short-Term Investments | 1.3B |
| Receivables | 751m |
| Other Current Assets | 767m |
| Non-Current Assets | 3.4B |
| Long-Term Investments | 273m |
| PP&E | 1.1B |
| Intangibles | 1.3B |
| Other Non-Current Assets | 640m |
| Current Liabilities | 2B |
| Accounts Payable | 218m |
| Accrued Liabilities | 428m |
| Other Current Liabilities | 1.3B |
| Non-Current Liabilities | 1.8B |
| Long-Term Debt | 994m |
| Other Non-Current Liabilities | 840m |
Free Cash Flow Analysis
Illumina Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Illumina Inc
|
Revenue
|
4.3B
USD
|
|
Cost of Revenue
|
-1.4B
USD
|
|
Gross Profit
|
2.9B
USD
|
|
Operating Expenses
|
-2B
USD
|
|
Operating Income
|
875m
USD
|
|
Other Expenses
|
-172m
USD
|
|
Net Income
|
703m
USD
|
ILMN Profitability Score
Profitability Due Diligence
Illumina Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Illumina Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
ILMN Solvency Score
Solvency Due Diligence
Illumina Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Illumina Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ILMN Price Targets Summary
Illumina Inc
According to Wall Street analysts, the average 1-year price target for
ILMN
is 126.28 USD
with a low forecast of 80.8 USD and a high forecast of 204.75 USD.
Dividends
Current shareholder yield for
ILMN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ILMN
stock under the Base Case scenario is
133.65
USD.
Compared to the current market price of 134.95 USD,
Illumina Inc
is
Overvalued by 1%.